CD8A and neoplasm: Deleting ACSS2 in tumor cells results in a switch from acetate consumption to acetate production by tumor cells, thereby increasing acetate as a fuel source for tumor-infiltrating CD8+ T cells and enhancing T cell proliferation and effector function (Miller et al., 2023).